-   Training & Support

[Expand/Collapse all sections]Expand all

For information on how to process a PBS Authority, see Processing
Complex Authority Required Listings. Contact Local Peer Support (LPS) if
unsure of how to action an application.

On this page:

Atypical haemolytic uraemic syndrome (aHUS) quick reference

Table 1

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Written   | Yes       | OPA       | Must be   | No        |
|           |           |           |           | treated   |           |
| PB119     | S100:     |           | Database  | by, or in |           |
| form      | e         |           |           | con       |           |
|           | culizumab |           |           | sultation |           |
|           |           |           |           | with a:   |           |
|           |           |           |           |           |           |
|           |           |           |           | -   p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Extended  | Written   | Yes       | OPA       | Must be   | No        |
| initial   |           |           |           | treated   |           |
|           | S100:     |           | Database  | by, or in |           |
| PB175     | e         |           |           | con       |           |
| form      | culizumab |           |           | sultation |           |
|           |           |           |           | with a:   |           |
|           |           |           |           |           |           |
|           |           |           |           | -   p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Written   | Yes       | OPA       | Must be   | No        |
| ontinuing |           |           |           | treated   |           |
|           | S100:     |           | Database  | by, or in |           |
| PB125     | e         |           |           | con       |           |
| form      | culizumab |           |           | sultation |           |
|           |           |           |           | with a:   |           |
|           |           |           |           |           |           |
|           |           |           |           | -   p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     Nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Recom     | Written   | Yes       | OPA       | Must be   | No        |
| mencement |           |           |           | treated   |           |
|           | S100:     |           | Database  | by, or in |           |
| PB176     | e         |           |           | con       |           |
| form      | culizumab |           |           | sultation |           |
|           |           |           |           | with a:   |           |
|           |           |           |           |           |           |
|           |           |           |           | -   p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     Nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Top up    | Written   | Yes       | OPA       | Must be   | No        |
|           |           |           |           | treated   |           |
|           | S100:     |           | Database  | by, or in |           |
|           | e         |           |           | con       |           |
|           | culizumab |           |           | sultation |           |
|           |           |           |           | with a:   |           |
|           |           |           |           |           |           |
|           |           |           |           | -   p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     nep   |           |
|           |           |           |           | hrologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     p     |           |
|           |           |           |           | aediatric |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
|           |           |           |           | -         |           |
|           |           |           |           |     haem  |           |
|           |           |           |           | atologist |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

aHUS disease phases

Table 2

+-----------------------------------+-----------------------------------+
| Treatment phase                   | Description                       |
+-----------------------------------+-----------------------------------+
| Initial criteria                  | -   4 week loading dose           |
|                                   |     available, 12 vials and nil   |
|                                   |     repeats, once patient has met |
|                                   |     criteria                      |
+-----------------------------------+-----------------------------------+
| Balance of supply                 | -   ADAMTS-13 test must be        |
|                                   |     supplied and patients are     |
|                                   |     then eligible for a further   |
|                                   |     20 weeks of treatment         |
|                                   | -    If ADAMTS-13 test is         |
|                                   |     provided when initial         |
|                                   |     paperwork is submitted,       |
|                                   |     approval can be given at the  |
|                                   |     same time as the initial      |
|                                   |     loading dose. Contact a       |
|                                   |     Pharmaceutical Advisor (PA),  |
|                                   |     if unsure                     |
|                                   | -    20 weeks of treatment        |
|                                   |     available (4 x repeats) can   |
|                                   |     be given under this           |
|                                   |     restriction i.e. 8 vials if > |
|                                   |     40kg. See the aHUS dosage     |
|                                   |     schedule table on the         |
|                                   |     Resources page if weight is < |
|                                   |     40kg                          |
+-----------------------------------+-----------------------------------+
| Extended initial 1                | -   Available to patients that    |
|                                   |     meet criteria after they have |
|                                   |     had the Balance of supply     |
|                                   | -    28 weeks treatment is        |
|                                   |     available (6 x repeats) under |
|                                   |     this restriction i.e. 8 vials |
|                                   |     if > 40kg. See the aHUS       |
|                                   |     dosage schedule table on the  |
|                                   |     Resources page if weight is < |
|                                   |     40kg                          |
+-----------------------------------+-----------------------------------+
| Extended initial 2                | -   Available to patients that    |
|                                   |     meet criteria after they have |
|                                   |     had treatment under extended  |
|                                   |     initial 1                     |
|                                   | -    28 weeks treatment available |
|                                   |     (6 x repeats) under this      |
|                                   |     restriction i.e. 8 vials if > |
|                                   |     40kg. See the aHUS dosage     |
|                                   |     schedule table on the         |
|                                   |     Resources page if weight is < |
|                                   |     40kg                          |
+-----------------------------------+-----------------------------------+
| Continuing                        | Available to patients that meet   |
|                                   | criteria after they’ve had the    |
|                                   | Extended initial 2                |
|                                   |                                   |
|                                   | 24 weeks treatment available (5 x |
|                                   | repeats) under this restriction.  |
|                                   | 8 vials if over 40kg. See dosage  |
|                                   | schedule if weight is < 40kg      |
|                                   |                                   |
|                                   | Patients have 3 options after     |
|                                   | having a total of 104 weeks of    |
|                                   | treatment, if the patient         |
|                                   | demonstrates a response, and also |
|                                   | the following:                    |
|                                   |                                   |
|                                   | -    no treatment failure, and    |
|                                   | -    has perilous organ damage,   |
|                                   |     or                            |
|                                   | -    a high risk of aHUS          |
|                                   |     recurrence in the short term  |
|                                   |     without eculizumab, they will |
|                                   |     be eligible for extended      |
|                                   |     continuing treatment          |
|                                   | -    demonstrate a response and   |
|                                   |     flare whilst off medication,  |
|                                   |     they will be eligible for     |
|                                   |     recommencement                |
|                                   | -    failed to respond, no        |
|                                   |     further treatment is          |
|                                   |     available                     |
+-----------------------------------+-----------------------------------+
| Extended Continuing               | Available to patients that have   |
|                                   | demonstrated a response to the    |
|                                   | medication and the following:     |
|                                   |                                   |
|                                   | -   had no treatment failures     |
|                                   | -    have perilous organ damage,  |
|                                   |     or                            |
|                                   | -    a high risk of aHUS          |
|                                   |     recurrence in the short term  |
|                                   |     without eculizumab            |
|                                   |                                   |
|                                   | Once patients are in this         |
|                                   | restriction ‘loop’, they are      |
|                                   | eligible for continuing criteria  |
|                                   | indefinitely if:                  |
|                                   |                                   |
|                                   | -   they demonstrate a response   |
|                                   |     every 24 weeks with no        |
|                                   |     treatment failure, and        |
|                                   | -    perilous organ damage, or    |
|                                   | -    a high risk of aHUS          |
|                                   |     recurrence in the short term  |
|                                   |     without eculizumab            |
|                                   |                                   |
|                                   | 24 weeks treatment is available   |
|                                   | (5 x repeats) under this          |
|                                   | restriction i.e. 8 vials if over  |
|                                   | 40kg. See the aHUS dosage         |
|                                   | schedule table on the Resources   |
|                                   | page if weight is < 40kg.         |
+-----------------------------------+-----------------------------------+
| Recommencement                    | -   Available for patients that   |
|                                   |     have had treatment with       |
|                                   |     eculizumab, demonstrated a    |
|                                   |     response to treatment and     |
|                                   |     flared while off eculizumab   |
|                                   | -    Patients may qualify for a   |
|                                   |     reload to the medication at   |
|                                   |     this stage. 12 vials and nil  |
|                                   |     repeats + 8 vials and 4       |
|                                   |     repeats (total of 24 weeks)   |
|                                   | -    24 weeks treatment is        |
|                                   |     available (5 x repeats) under |
|                                   |     this restriction. That is, 8  |
|                                   |     vials if > 40kg. See the aHUS |
|                                   |     dosage schedule table on the  |
|                                   |     Resources page if weight is < |
|                                   |     40kg                          |
+-----------------------------------+-----------------------------------+
| Recommencement Continuing         | -   Once patients are in this     |
|                                   |     restriction 'loop' they are   |
|                                   |     eligible for continuing       |
|                                   |     criteria indefinitely if they |
|                                   |     demonstrate a response every  |
|                                   |     24 weeks with no treatment    |
|                                   |     failure                       |
|                                   | -    24 weeks treatment is        |
|                                   |     available (5 x repeats) under |
|                                   |     this restriction. 8 vials     |
|                                   |     if > 40kg. See the aHUS       |
|                                   |     dosage schedule table on the  |
|                                   |     Resources page if weight is < |
|                                   |     40kg                          |
+-----------------------------------+-----------------------------------+
| Treatment failure                 | If the patient was assessed for a |
|                                   | response and failed; they must    |
|                                   | cease treatment and are no longer |
|                                   | eligible for further treatment. A |
|                                   | PA will determine this, and will  |
|                                   | record a database entry 'failed   |
|                                   | to respond'.                      |
+-----------------------------------+-----------------------------------+
| Demonstrating a response          | -   At any stage during the       |
|                                   |     patient’s treatment, the      |
|                                   |     prescriber can elect to send  |
|                                   |     a demonstration of response   |
|                                   | -    If the patient flares, they  |
|                                   |     will be eligible to go on the |
|                                   |     recommencement restriction if |
|                                   |     they meet criteria            |
|                                   | -    The prescriber may also      |
|                                   |     elect to send the             |
|                                   |     demonstration of response     |
|                                   |     through when the patient      |
|                                   |     flares                        |
|                                   | -    Update the previous database |
|                                   |     line to 'Responded not        |
|                                   |     current'                      |
+-----------------------------------+-----------------------------------+
| Add on                            | -   Patients are able to increase |
|                                   |     their dose while receiving a  |
|                                   |     plasma exchange. This will be |
|                                   |     classified as an 'add on', no |
|                                   |     weeks to be entered into the  |
|                                   |     database                      |
|                                   | -    A request would need to be   |
|                                   |     submitted in writing and      |
|                                   |     reviewed by a PA              |
|                                   | -    To approve, use the previous |
|                                   |     item and restriction codes    |
|                                   |     the patient was approved      |
|                                   |     under                         |
+-----------------------------------+-----------------------------------+

Applications completed on the database

Table 3

+-----------------------------------+-----------------------------------+
| Application type                  | Action                            |
+-----------------------------------+-----------------------------------+
| Initial                           | -   Create a patient record on    |
|                                   |     the database if required      |
|                                   | -    Create a new pended entry in |
|                                   |     the database                  |
|                                   | -    Send to a Pharmaceutical     |
|                                   |     Advisor (PA) for assessment   |
|                                   |                                   |
|                                   | Once application has been         |
|                                   | assessed by PA, complete the      |
|                                   | entry in the database.            |
+-----------------------------------+-----------------------------------+
| Extended initial 1 and 2          | -   Create a new pended entry in  |
|                                   |     the database                  |
|                                   | -    Send to a Pharmaceutical     |
|                                   |     Advisor (PA) for assessment   |
|                                   |                                   |
|                                   | Once application has been         |
|                                   | assessed by PA, complete the      |
|                                   | entry in the database.            |
+-----------------------------------+-----------------------------------+
| Continuing and Extended           | -   Create a new pended entry in  |
| Continuing                        |     the database                  |
|                                   | -    Send to a Pharmaceutical     |
|                                   |     Advisor (PA) for assessment   |
|                                   |                                   |
|                                   | Once application has been         |
|                                   | assessed by PA, complete the      |
|                                   | entry in the database.            |
+-----------------------------------+-----------------------------------+
| Recommencement                    | -   Create a new pended entry in  |
|                                   |     the database                  |
|                                   | -    Send to a PA for assessment  |
|                                   |                                   |
|                                   | Once application has been         |
|                                   | assessed by PA, complete the      |
|                                   | entry in the database.            |
+-----------------------------------+-----------------------------------+
| Add on/top ups                    | Update the previous line in the   |
|                                   | database.                         |
+-----------------------------------+-----------------------------------+
| Demonstration of Response         | Create and complete a new entry   |
|                                   | in the database.                  |
+-----------------------------------+-----------------------------------+

                                   

-   Services Australia ABN 90 794 605 008 
